Mechanisms that enable CRPCs to activate AR and continually acquire resistance to therapies underscore the importance of gaining a comprehensive understanding of the downstream effectors of AR signaling that play crucial roles in cancer progression, as they could serve as druggable targets in the treatment of CRPC. This evidence concerns the gene AR and cancer.